Agilent: US FDA approves Agilent's PDL1 IHC 288 pharmDx assay in ESCC, gastric, GEJ and esophageal adenocarcinoma
Agilent Technologies Inc., a global leader in analytical and clinical laboratory technologies, announced that it has received US Food and Drug Administration (FDA) approval for the PD─L1 IHC 28─8 pharmDx assay
Read full article »
Agilent is a California-based biotechnology company that manufactures and supplies bio-analytical measurement equipment for sectors such as chemical and pharmaceutical.
Read more